An immune signature to predict the prognosis of
ATRX wildtype
glioma
immune checkpoint blockade therapy
immunity
signature
Journal
Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617
Informations de publication
Date de publication:
06 10 2023
06 10 2023
Historique:
received:
01
05
2023
accepted:
21
08
2023
medline:
23
10
2023
pubmed:
9
10
2023
entrez:
9
10
2023
Statut:
ppublish
Résumé
Immune and stromal cells contribute to glioma progression by infiltrating the tumor microenvironment. We used clinical characteristics, RNA sequencing data and the ESTIMATE algorithm to obtain stromal and immune scores for alpha thalassemia retardation syndrome X-linked (
Identifiants
pubmed: 37812190
pii: 205088
doi: 10.18632/aging.205088
pmc: PMC10599764
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
X-linked Nuclear Protein
EC 3.6.4.12
ATRX protein, human
EC 3.6.4.12
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10453-10472Références
Brief Bioinform. 2021 Nov 5;22(6):
pubmed: 34260682
Proc Natl Acad Sci U S A. 2021 Nov 9;118(45):
pubmed: 34740973
Nat Cell Biol. 2019 Sep;21(9):1113-1126
pubmed: 31451770
Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11939-44
pubmed: 17609377
Nucleic Acids Res. 2022 Nov 28;50(21):12217-12234
pubmed: 36440760
Cancers (Basel). 2023 Apr 10;15(8):
pubmed: 37190157
Int J Biol Sci. 2020 Feb 24;16(8):1474-1480
pubmed: 32210734
Oncol Rep. 2020 Aug;44(2):611-627
pubmed: 32627011
Trends Genet. 2023 Jun;39(6):505-519
pubmed: 36894374
Bioengineered. 2021 Dec;12(2):9692-9708
pubmed: 34696669
Cancer Res. 2022 Sep 16;82(18):3321-3334
pubmed: 35841593
Science. 2011 Mar 4;331(6021):1199-203
pubmed: 21252315
Sci Rep. 2016 Oct 26;6:35807
pubmed: 27782156
Gynecol Oncol. 2021 Feb;160(2):530-538
pubmed: 33317907
Int Immunopharmacol. 2020 Jul;84:106490
pubmed: 32289666
J Cell Mol Med. 2017 Sep;21(9):2184-2198
pubmed: 28338293
J Hepatol. 2022 Sep;77(3):683-694
pubmed: 35430299
Nat Commun. 2022 Aug 26;13(1):5033
pubmed: 36028493
Front Oncol. 2021 Nov 01;11:771528
pubmed: 34790580
Cancer Sci. 2022 Jun;113(6):2167-2178
pubmed: 35384159
Bioengineered. 2022 May;13(5):12193-12210
pubmed: 35549979
Int J Oncol. 2012 Apr;40(4):1180-8
pubmed: 22227861
Neurooncol Adv. 2020 Jan 24;2(1):vdz059
pubmed: 32642724
Histol Histopathol. 2020 Sep;35(9):997-1005
pubmed: 32378728
Nature. 2017 Jul 27;547(7664):413-418
pubmed: 28723893
Cancer Res. 2021 Jul 1;81(13):3635-3648
pubmed: 34006525
Genome Biol. 2021 Nov 11;22(1):311
pubmed: 34763709
Acta Neuropathol. 2023 Jan;145(1):71-82
pubmed: 36271929
Int J Mol Sci. 2019 Jan 08;20(1):
pubmed: 30625996
BMC Cancer. 2020 Nov 9;20(1):1072
pubmed: 33167941
Expert Opin Ther Targets. 2018 Jul;22(7):599-613
pubmed: 29889582
EMBO J. 2012 Jan 18;31(2):481-93
pubmed: 22085929
Signal Transduct Target Ther. 2022 Mar 16;7(1):74
pubmed: 35292619
Int J Mol Sci. 2021 Sep 26;22(19):
pubmed: 34638714
J Cell Mol Med. 2023 Jul;27(13):1820-1835
pubmed: 37248957
Cancer Metastasis Rev. 2022 Mar;41(1):53-75
pubmed: 34687436
Neuro Oncol. 2023 Feb 14;25(2):263-276
pubmed: 35609569